RIGL
Rigel Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+40/100
Last price
46.11
▼ 1.68 (3.52%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
48.18
Prev close
47.79
Day high
48.18
Day low
45.93
Volume
202.60K
Market cap
$861.33M
P/E (TTM)
2.73
52W range
24.95 – 52.24
Day trading desk
Gap from prior close
+0.82%
Prior close 47.79
VWAP
46.51
-0.85% from price
Relative volume
0.57×
Quiet session
Session range
4.90%
45.93 – 48.18
Position in range
8%
Near session low
ATR (14D)
1.70
3.68% of price
Prior day high
48.83
PDH
Prior day low
46.93
PDL
Bid / ask spread
—
Quote not published
Session volume
166.20K
Avg 291.93K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.69%
-7.6%
1M
-5.26%
-6.4%
3M
+7.41%
+2.9%
6M
+60.49%
+42.3%
YTD
+7.66%
-6.6%
1Y
+61.56%
+45.1%
3Y
+326.94%
+244.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RIGL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+67.63K
Net buying
Buy transactions
10
72.63K shares
Sell transactions
2
5.00K shares
Net transactions
+12
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
626.15K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | SCHORNO DEAN L Chief Financial Officer |
CONVERSION | 4.60K | $99.93K | Direct |
| Jul 8, 26 | HANNAH ALISON L. Officer |
STOCK | 24.40K | $0 | Direct |
| Jun 22, 26 | ALI-JACKSON KAMIL Director |
SELL | 2.50K | $87.50K | Direct |
| Jun 1, 26 | SCHORNO DEAN L Chief Financial Officer |
CONVERSION | 3.38K | $50.14K | Direct |
| May 26, 26 | ALI-JACKSON KAMIL Director |
SELL | 2.50K | $72.92K | Direct |
| May 15, 26 | MOOS WALTER H Director |
STOCK | 5.75K | $0 | Direct |
| May 15, 26 | MILLER MICHAEL PATRICK Director |
STOCK | 5.75K | $0 | Direct |
| May 15, 26 | FROHLICH MARK W Director |
STOCK | 5.75K | $0 | Direct |
| May 15, 26 | LAPOINTE ANTHONY GREGG Director |
STOCK | 5.75K | $0 | Direct |
| May 15, 26 | WASMAN JANE Director |
STOCK | 5.75K | $0 | Direct |
| May 15, 26 | HANNAH ALISON L. Director |
STOCK | 5.75K | $0 | Direct |
| May 15, 26 | ALI-JACKSON KAMIL Director |
STOCK | 5.75K | $0 | Direct |
| Feb 20, 26 | MOOS WALTER H Director |
CONVERSION | 4.00K | $96.00K | Direct |
| Feb 20, 26 | MOOS WALTER H Director |
SELL | 4.00K | $145.44K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALI-JACKSON KAMIL |
Director | 10.13K | Sale |
FUREY RAYMOND J |
General Counsel | 51.81K | Stock Award(Grant) |
HANNAH ALISON L. |
Officer | 35.02K | Stock Award(Grant) |
LAPOINTE ANTHONY GREGG |
Director | 18.25K | Stock Award(Grant) |
MOOS WALTER H |
Director | 18.47K | Stock Award(Grant) |
RODRIGUEZ RAUL R |
Chief Executive Officer | 282.02K | Stock Award(Grant) |
ROJKJAER LISA |
Officer | 34.85K | Stock Award(Grant) |
SANTOS DAVID A |
Officer | 62.87K | Stock Award(Grant) |
SCHORNO DEAN L |
Chief Financial Officer | 82.96K | Conversion of Exercise of derivative security |
WASMAN JANE |
Director | 18.25K | Stock Award(Grant) |
Fundamentals
Market cap$861.33M
Enterprise value$805.95M
Revenue (TTM)$276.78M
Gross profit$209.27M
EBITDA$89.70M
Net income$321.91M
EPS (TTM)$16.88
Free cash flow$-31.76M
Total cash$95.33M
Total debt$39.95M
Book value / share$22.81
Shares outstanding18.68M
Float14.84M
Short % of float17.54%
Dividend yield0.00%
Beta (5Y)1.19
Valuation & profitability ratios
Trailing P/E2.73
Forward P/E9.34
PEG ratio—
Price / sales—
Price / book2.02
EV / revenue2.91
EV / EBITDA8.99
Gross margin75.61%
Operating margin29.95%
Profit margin116.30%
Return on equity126.90%
Return on assets14.95%
Debt / equity9.39
Current ratio1.94
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $294.28M | $179.28M | $116.88M | $120.24M | +64.1% |
| Operating revenue | $372.26M | $244.30M | $159.65M | $152.05M | +52.4% |
| Cost of revenue | $19.62M | $18.65M | $7.11M | $1.75M | +5.2% |
| Gross profit | $274.66M | $160.63M | $109.77M | $118.49M | +71.0% |
| Research & development | $33.30M | $23.38M | $24.52M | $60.27M | +42.4% |
| Selling, general & admin | $115.90M | $113.06M | $105.74M | $112.45M | +2.5% |
| Total operating expense | $149.19M | $136.44M | $130.26M | $172.72M | +9.3% |
| Operating income | $125.47M | $24.19M | -$20.49M | -$54.23M | +418.6% |
| Net interest income | -$3.64M | -$5.83M | -$4.60M | -$3.02M | +37.5% |
| Pre-tax income | $121.83M | $18.37M | -$25.09M | -$58.57M | +563.3% |
| Tax provision | -$245.20M | $881.00K | $0 | $0 | -27,931.7% |
| Net income | $367.02M | $17.48M | -$25.09M | -$58.57M | +1,999.1% |
| Net income to common | $367.02M | $17.48M | -$25.09M | -$58.57M | +1,999.1% |
| Basic EPS | 20.40 | 0.99 | -1.44 | -3.40 | +1,960.6% |
| Diluted EPS | 19.48 | 0.99 | -1.44 | -3.40 | +1,867.7% |
| EBIT | $129.15M | $26.28M | -$18.22M | -$54.87M | +391.4% |
| EBITDA | $131.56M | $28.51M | -$16.98M | -$53.87M | +361.4% |
| Basic shares | 17.99M | 17.58M | 17.40M | 17.24M | +2.3% |
| Diluted shares | 18.84M | 17.69M | 17.40M | 17.24M | +6.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $40.58M | $56.75M | $32.79M | $24.46M | -28.5% |
| Cash & short-term investments | $154.96M | $77.32M | $56.93M | $58.21M | +100.4% |
| Accounts receivable | $51.76M | $41.62M | $30.55M | $40.32M | +24.4% |
| Inventory | $11.51M | $6.00M | $5.52M | $9.12M | +91.7% |
| Total current assets | $240.17M | $135.10M | $99.27M | $115.90M | +77.8% |
| Property, plant & equipment | $920.00K | $246.00K | $1.03M | $2.79M | +274.0% |
| Goodwill & intangibles | $24.75M | $27.10M | $13.88M | $14.95M | -8.7% |
| Total assets | $513.59M | $163.98M | $117.22M | $134.28M | +213.2% |
| Total current liabilities | $99.24M | $63.30M | $53.27M | $65.21M | +56.8% |
| Current debt | $29.81M | $7.27M | $7.23M | — | +310.0% |
| Long-term debt | $22.48M | $52.41M | $52.37M | $39.45M | -57.1% |
| Total debt | $53.30M | $59.97M | $60.58M | $41.55M | -11.1% |
| Total liabilities | $122.11M | $160.69M | $145.87M | $147.90M | -24.0% |
| Retained earnings | -$1.02B | -$1.39B | -$1.41B | -$1.38B | +26.4% |
| Shareholder equity | $391.48M | $3.29M | -$28.64M | -$13.62M | +11,806.3% |
| Working capital | $140.93M | $71.80M | $46.00M | $50.69M | +96.3% |
| Net tangible assets | $366.73M | -$23.81M | -$42.52M | -$28.57M | +1,640.1% |
| Shares issued | 18.31M | 17.71M | 17.48M | 17.34M | +3.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $367.02M | $17.48M | -$25.09M | -$58.57M | — | +1,999.1% |
| Depreciation & amortisation | $2.42M | $2.23M | $1.24M | $998.00K | — | +8.4% |
| Stock-based compensation | $12.71M | $12.39M | $8.81M | $12.38M | — | +2.6% |
| Change in working capital | -$19.51M | $153.00K | $9.52M | -$29.05M | — | -12,852.9% |
| Operating cash flow | $75.66M | $31.47M | -$5.74M | -$73.76M | — | +140.4% |
| Capital expenditure | — | -$396.00K | -$15.00M | -$450.00K | -$627.00K | — |
| Investing cash flow | -$92.36M | $4.13M | -$4.30M | $72.78M | — | -2,336.4% |
| Share buybacks | $0 | -$10.00M | $0 | $0 | — | +100.0% |
| Financing cash flow | $601.00K | -$11.64M | $18.37M | $6.55M | — | +105.2% |
| Free cash flow | $75.66M | $31.07M | -$20.74M | -$74.21M | — | +143.5% |
| End cash position | $40.64M | $56.75M | $32.79M | $24.46M | — | -28.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $78.70M | $58.82M | $69.80M | $69.46M | $101.69M | +33.8% |
| Operating revenue | $100.15M | $79.28M | $88.84M | $91.02M | $122.43M | +26.3% |
| Cost of revenue | $8.53M | $4.61M | $5.96M | $4.75M | $4.50M | +85.1% |
| Gross profit | $70.18M | $54.21M | $63.85M | $64.71M | $97.18M | +29.5% |
| Research & development | $13.96M | $11.68M | $10.69M | $7.35M | $6.82M | +19.6% |
| Selling, general & admin | $32.64M | $30.65M | $29.99M | $28.94M | $29.26M | +6.5% |
| Total operating expense | $46.60M | $42.33M | $40.68M | $36.29M | $36.08M | +10.1% |
| Operating income | $23.57M | $11.88M | $23.17M | $28.42M | $61.10M | +98.4% |
| Net interest income | $10.00K | -$228.00K | -$456.00K | -$800.00K | -$1.12M | +104.4% |
| Pre-tax income | $23.59M | $11.66M | $22.71M | $27.62M | $59.98M | +102.3% |
| Tax provision | $6.29M | $3.00M | -$245.35M | -$280.00K | $369.00K | +109.6% |
| Net income | $17.29M | $8.65M | $268.06M | $27.90M | $59.61M | +99.8% |
| Net income to common | $17.29M | $8.65M | $268.06M | $27.90M | $59.61M | +99.8% |
| Basic EPS | 0.93 | 0.47 | 14.72 | 1.55 | 3.33 | +97.9% |
| Diluted EPS | 0.88 | 0.44 | 13.54 | 1.46 | 3.28 | +100.0% |
| EBIT | $24.36M | $13.09M | $24.41M | $29.51M | $61.86M | +86.1% |
| EBITDA | $25.21M | $13.69M | $25.01M | $30.12M | $62.46M | +84.2% |
| Basic shares | 18.54M | 18.41M | 18.21M | 18.04M | 17.89M | +0.7% |
| Diluted shares | 19.57M | 19.69M | 19.79M | 19.16M | 18.16M | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $60.82M | $24.41M | $40.58M | $48.53M | $53.41M | — | +149.1% |
| Cash & short-term investments | $95.33M | $146.68M | $154.96M | $137.14M | $108.38M | — | -35.0% |
| Accounts receivable | $56.04M | $49.95M | $51.76M | $45.92M | $39.91M | — | +12.2% |
| Inventory | $14.37M | $11.65M | $11.51M | $13.30M | $10.42M | — | +23.3% |
| Total current assets | $185.53M | $234.03M | $240.17M | $214.93M | $175.39M | — | -20.7% |
| Property, plant & equipment | $647.00K | $785.00K | $920.00K | $1.10M | $1.24M | — | -17.6% |
| Goodwill & intangibles | $93.88M | $24.16M | $24.75M | $25.34M | $25.92M | — | +288.6% |
| Total assets | $521.07M | $504.61M | $513.59M | $242.53M | $206.74M | — | +3.3% |
| Total current liabilities | $95.59M | $89.49M | $99.24M | $94.40M | $86.64M | — | +6.8% |
| Current debt | $39.24M | $29.86M | $29.81M | $29.76M | $22.36M | — | +31.4% |
| Long-term debt | — | $14.99M | $22.48M | $29.97M | $37.45M | $44.93M | — |
| Total debt | $39.95M | $45.72M | $53.30M | $60.88M | $61.04M | — | -12.6% |
| Total liabilities | $95.64M | $104.71M | $122.11M | $124.92M | $124.80M | — | -8.7% |
| Retained earnings | -$997.10M | -$1.01B | -$1.02B | -$1.29B | -$1.32B | — | +1.7% |
| Shareholder equity | $425.42M | $399.90M | $391.48M | $117.61M | $81.93M | — | +6.4% |
| Working capital | $89.94M | $144.53M | $140.93M | $120.53M | $88.76M | — | -37.8% |
| Net tangible assets | $331.54M | $375.74M | $366.73M | $92.27M | $56.01M | — | -11.8% |
| Shares issued | 18.65M | 18.48M | 18.31M | 18.14M | 17.94M | — | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $17.29M | $8.65M | $268.06M | $27.90M | $59.61M | — | +99.8% |
| Depreciation & amortisation | $848.00K | $597.00K | $601.00K | $603.00K | $607.00K | — | +42.0% |
| Stock-based compensation | $6.84M | $3.46M | $2.75M | $3.36M | $3.28M | — | +98.0% |
| Change in working capital | $286.00K | -$12.38M | -$3.34M | -$7.37M | $7.27M | — | +102.3% |
| Operating cash flow | $30.65M | $2.73M | $21.98M | $24.03M | $30.54M | — | +1,024.9% |
| Investing cash flow | $17.45M | -$7.97M | -$25.36M | -$33.17M | -$23.28M | — | +318.8% |
| Share buybacks | -$511.00K | -$3.74M | — | — | $0 | $0 | +86.3% |
| Financing cash flow | -$11.70M | -$10.92M | -$4.57M | $4.27M | $418.00K | — | -7.2% |
| Free cash flow | -$39.69M | $2.73M | $21.99M | $24.02M | $30.54M | — | -1,556.7% |
| End cash position | $60.87M | $24.47M | $40.64M | $48.59M | $53.46M | — | +148.8% |
Options analytics
Put / call volume
0.14
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
30.00
-34.9% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
71
Contracts, this expiry
Put volume
10
Contracts, this expiry
Heaviest call OI
30.00
0 contracts
Heaviest put OI
30.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | 0.88 | +1,266.8% |
| Mar 2026 | 0.87 | 0.44 | -49.5% |
| Dec 2025 | 1.20 | 1.12 | -6.8% |
| Sep 2025 | 0.94 | 1.46 | +56.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.96 | 4 | $80.10M | +15.3% |
| Next quarter | 1.04 | 4 | $88.12M | +26.3% |
| Current year | 3.54 | 4 | $305.73M | +3.9% |
| Next year | 4.94 | 4 | $372.84M | +22.0% |
Analyst targets & ownership
Mean target$63.00
High target$85.00
Low target$43.00
Implied upside36.63%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 3
Hold2
Sell / Strong sell0 / 0
Held by insiders3.35%
Held by institutions89.27%
Institutions holding226
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
47.86
-3.66% from price
SMA 20
47.15
-2.20% from price
SMA 50
44.88
+2.75% from price
SMA 100
39.91
+15.52% from price
SMA 200
36.59
+26.03% from price
EMA 12
47.40
-2.73% from price
EMA 26
46.79
-1.46% from price
EMA 50
44.91
+2.66% from price
RSI (14)
47.1
Neutral
MACD (12,26,9)
0.61
Hist -0.30
ATR (14)
1.70
3.68% of price
Realised vol 30D
33.0%
Annualised
Bollinger upper
49.83
20, 2σ
Bollinger lower
44.47
20, 2σ
50 / 200 cross
Golden
44.88 vs 36.59
Trend bias
Above 200
+26.03%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.71
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
33.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.1%
Peak to trough
Max drawdown 5Y
-81.2%
Peak to trough
ATR 14
1.70
3.68% of price
Beta (reported)
1.19
5Y monthly, from filing
Short interest
Shares short
3.19M
Prior 3.20M
Change vs prior
-0.4%
Shorts covering
% of float
17.54%
Elevated
% of shares out
17.09%
Against total outstanding
Days to cover
11.4
Crowded exit
Float
14.84M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Aug 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Nov 5, 25 | Jefferies | UPGRADE | Hold | Buy |
| Nov 5, 25 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
| Oct 8, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 6, 25 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
| May 7, 25 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJun 27, 2024
SEC filings
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-20
Corporate Changes & Voting Matters
8-K · 2026-05-12
Periodic Financial Reports
10-Q · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-04-21
Proxy Statements
DEF 14A · 2026-04-03
Headlines
Knight Therapeutics Announces Launch of TAVALISSE® in Brazil
GlobeNewswire · 18h ago
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PR Newswire · 5d ago
Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight
PR Newswire · 22d ago
Rigel to Participate in Upcoming September Investor Conferences
PR Newswire · 35d ago
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope
Simply Wall St. · 52d ago
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
BioPharma Dive · 54d ago
Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico
MT Newswires · 55d ago
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
PR Newswire · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.